Final results of a phase Ib/IIa study of phenoxodiol in hormone-refractory prostate cancer.

被引：0
|
作者：
Davies, R
Tulloch, A
Frydenberg, M
Kelly, G
机构：
[1] Sir Charles Gairdiner Hosp, Perth, WA, Australia
[2] St John God Hosp, Perth, WA, Australia
[3] Monash Med Ctr, Melbourne, Vic, Australia
[4] Marshall Edwards Inc, Sydney, NSW, Australia
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9123S / 9123S
页数：1
相关论文
共 50 条
  • [41] A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer
    Berry, William
    Friedland, David
    Fleagle, John
    Jackson, Dori
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 131 - 137
  • [42] Endothelial FSH receptor expression and vascular remodeling in hormone-refractory prostate cancer.
    Ghinea, Nicolae
    Robin, Blaise
    Planeix, Francois
    Brito, Isabel
    Pichon, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
    Colleoni, M
    Graiff, C
    Vicario, G
    Nelli, P
    Sgarbossa, G
    Pancheri, F
    Manente, P
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04): : 383 - 386
  • [44] Pilot study of rapamycin in patients with hormone-refractory prostate cancer
    Amato, Robert J.
    Jac, Jaroslaw
    Mohammad, Taqi
    Saxena, Somya
    CLINICAL GENITOURINARY CANCER, 2008, 6 (02) : 97 - 102
  • [45] A phase II study of paclitaxel and vinorelbine (Pac-Vin) in hormone-refractory metastatic prostate cancer (HRPC): A final update
    Sewak, S.
    Kosmider, S.
    Ganju, V.
    Woollett, A.
    Le, B.
    Yeo, E.
    Henry, M.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Treatment with prednisolone of hormone-refractory prostate cancer
    Fuse, H
    Nozaki, T
    Fujiuchi, Y
    Mizuno, I
    Nagakawa, O
    Okumura, A
    ARCHIVES OF ANDROLOGY, 2006, 52 (01): : 35 - 38
  • [47] Octreotide in the management of hormone-refractory prostate cancer
    Vainas, IG
    CHEMOTHERAPY, 2001, 47 : 109 - 126
  • [48] The androgen receptor in hormone-refractory prostate cancer
    Mao, Hai-Lei
    Zhu, Zhi-Qi
    Chen, Charlie Degui
    ASIAN JOURNAL OF ANDROLOGY, 2009, 11 (01) : 68 - 73
  • [49] Docetaxel (Taxotere) in hormone-refractory prostate cancer
    Petrylak, DP
    SEMINARS IN ONCOLOGY, 2000, 27 (02) : 24 - 29
  • [50] Revolutions in the management of hormone-refractory prostate cancer
    Abrahamsson, PA
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 1 - 2
12345